According to Actover Group’s Public Relations Department, the event brought together participants, physicians and pharmacists from across the Group to highlight the importance of early

The Medical Director of Actoverco emphasized that effective pharmacovigilance goes beyond regulatory compliance and requires a strong organizational culture in which all departments actively contribute

Alborz Zagros, a member of Actoverco Pharmaceutical Group, has introduced Upavoq (Upadacitinib), an oral selective Janus Kinase (JAK) inhibitor, to the Iranian pharmaceutical market. Available

TEHRAN, Iran – Actover Pharmaceutical Group participated in the 11th International Exhibition of Pharmaceuticals and Related Industries (Iran Pharma), held from September 23 to 25

Actoverco Pharmaceutical Group officially unveiled its injectable medications Tirzacto (Tirzepatide) and Semacto (Semaglutide) during a ceremony held in conjunction with National Physicians' Day. The event

Actoverco Pharmaceutical Company has manufactured and launched Rezmiver (Resmetirom), providing eligible patients in Iran with access to the first FDA-approved medication for the treatment of